



A new funding
for innovative and collaborative
neurodegenerative disease projects

What is NeurATRIS?

NeurATRIS (<http://neuratris.com>), a French Research Infrastructure in Biology and Health, is dedicated to **innovation in translational neuroscience** and gathers cutting-edge core facilities from 6 worldwide-prestigious research centers (CEA, ICM, BIRD, Robert Debré, Necker Enfants Malades and Henri Mondor Hospitals). These centers mutualize their technologies and scientific expertise to support innovative research projects in neurodegenerative diseases – Alzheimer, Parkinson, Huntington and Multiple Sclerosis – ranging from basic science proof-of-concepts to clinical applications, in the 4 following areas:

- **Cell therapies**
- **Gene therapy**
- **Drug-based therapies**
- **Assessment of disease processes and therapeutic efficacy**

Come and play with NeurATRIS!

NeurATRIS launches a call aimed at fostering **collaborative projects between NeurATRIS members and scientific community** involved in neurodegenerative disease projects.

Academic research laboratories and biotechs are welcome to apply. Applicant consortia may include a private partner, but only academics and biotechs will be eligible for funding.

Successful applicants will have **access to high quality technological platforms**, expertise and support from NeurATRIS partners, such as advanced neuroimaging technologies, HTS/HCS, cell and animal models, behavioral testing, viral vectors core facilities, etc.

Selected research teams will have access to core facilities in one or several NeurATRIS research centers.

NeurATRIS grants, up to 50 000 €, will be dedicated to cover platform costs, excluding consumables and animal purchase. Small equipment costs are allowed but should be limited to less than 20% of the total grant amount (individual equipment < 4k€). The budget may also include travel and accommodation costs (up to 10% of the total grant amount).

Can I apply?

- Projects can be submitted by academic or clinical research laboratories and biotechs, and must involve at least two partners.
- **Co-financing is mandatory**, as consumable fees are not included in NeurATRIS grants.
- **All expenses have to be paid by October 2019.**
- The institution managing the allocated NeurATRIS grant must be able to issue an invoice to CEA in order to be paid. NeurATRIS will take in charge platforms fees.

What does NeurATRIS expect in return?

- NeurATRIS grant beneficiaries are committed to present their work during **at least one NeurATRIS annual meeting** (fall 2018 and 2019) and will contribute shortly (5 lines) in the **ANR NeurATRIS report**.
- All related written and verbal communication (publications, posters and congress, etc.) should mention NeurATRIS support.

How do I apply?

Send the **completed application form** to Lauranne Duquenne, NeurATRIS project manager (lauranne.duquenne@cea.fr).

Projects will be reviewed by NeurATRIS executive committee **once a month**.

Application form: description of the project
3 pages max.

1. General description

- **Title:**
- **Category:**
cell therapies / gene therapy / assessment of disease processes and therapeutic efficacy / drug-based therapies
- **Keywords:**
- **Duration:** (2 years max)
- **Involved teams / labs / companies:**
- **Project leaders:**
- **Project participants:**

Name	Team / Lab / Company	Status

2. Detailed description

- **Scientific summary of the project:**
(Context, scientific objectives, technical approach, originality, etc.)
- **NeurATRIS core facilities considered for the project:**
- **NeurATRIS research teams associated to the project:**

3. BUDGET

- **Total estimated budget:**
- **Other financial sources:**
- **Requested budget:**

Description of the expenses	Unit price	Quantity	Total
Total requested			

Eligible expenses: access to NeurATRIS core facilities, small equipment < 4k€, travel expenses
Ineligible expenses: staff, equipment > 4k€, consumables and animals